The characteristics of genotype V Japanese encephalitis virus (GV JEV) remain poorly understood as only two strains have been isolated to date. In this study, we examined the effects of the GV JEV Muar strain on in vitro growth and pathogenicity in mice; we also evaluated the efficacy of inactivated JEV vaccines against the Muar strain. Although growth of the Muar strain in mouse neuroblastoma N18 cells was clearly worse than that of the GIII Beijing-1 and GI Mie/41/2002 strains, neuroinvasiveness of the Muar strain was similar to that of the Beijing-1 strain and significantly higher than that of the Mie/41/2002 strain. The results of a plaque reduction neutralization test suggested that the neutralization ability of the JEV vaccines against the Muar strain was reduced compared with the GI and GIII strains. However, the protection potency of the JEV vaccine against the Muar strain was similar to that for the Beijing-1 strain in mice. Our data indicate that GV JEV has unique growth, virulence and antigenicity features.
INTRODUCTION
Japanese encephalitis (JE), resulting from infection with Japanese encephalitis virus (JEV), is a significant public health problem in many Asian countries. JEV causes serious nervous disorders such as meningitis and encephalitis. There are an estimated 68 000 cases of JE per year, occurring mainly in China, India and South-east Asian countries, which result in 15 000 fatalities, mostly in children (Campbell et al., 2011; Erlanger et al., 2009; Tsai, 2000) . There is no specific treatment available for JE, other than preventative vaccination with JEV vaccines. In Japan, the number of reported JE cases has decreased dramatically since the late 1960s, and fewer than 10 JE cases have occurred in Japan over the past two decades (Arai et al., 2008) . This decrease is thought to be due to active vaccination, a decrease in the number of mosquitoes that can transmit JEV and urbanization. However, a study on the prevalence of JEV that used domestic pigs indicated that, in most regions of Japan, naive pigs are still seroconverted to JEV every year, which suggests that JEV remains a serious threat (Arai et al., 2008) .
JEV belongs to the genus Flavivirus in the family Flaviviridae and is amplified in a bird and pig-mosquito transmission cycle (Pierson & Diamond, 2013) . The infected mosquitoes, mainly Culex tritaeniorhynchus, transmit JEV to dead-end hosts: either humans or horses. JEV has a positive-sense ssRNA genome, which encodes three structural proteins (C, prM and E) and seven non-structural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5). JEV is classified into five genotypes (GI-GV) based on its genomic sequence (Solomon et al., 2003) , of which the GIII strain was the most widely distributed and most frequently isolated in JE endemic areas until the 1990s. Consequently, all licensed inactivated and live-attenuated JE vaccines are derived from GIII JEV. However, the major genotype of JEV isolated in Japan changed from GIII to GI in the early 1990s (Ma et al., 2003; Yoshida et al., 2005) . In recent years, a similar genotype shift has been observed in South Korea, northern Vietnam, China, Taiwan and Thailand Nam et al., 1996; Nga et al., 2004; Nitatpattana et al., 2008; Pan et al., 2011; Wang et al., 2007; Yang et al., 2004; Yun et al., 2010; Zhang et al., , 2011 . GI JEV has also been found in India since 2009 (Fulmali et al., 2011) . Thus, the dominant genotype in JEV endemic areas is now GI, although the reasons for the broad shift from GIII to GI remain unclear. The Indonesian/Malaysian region is thought to be the origin of all genotypes of JEV (Solomon et al., 2003) , and in several South-east Asian countries, GI was isolated as a minor JEV strain before the 1990s. Comprehensive phylogenetic analysis of the GI JEV strains has demonstrated that the old and the new GI strains form distinct lineages (Gao et al., 2013; Schuh et al., 2014) , suggesting that genetic differences in the new GI genome might be responsible for the spread of GI viruses. Recent findings indicate that GI JEV exhibits a higher replicative ability in mosquitoes than GIII JEV (Schuh et al., 2014) .
A GV strain of JEV was first isolated from an encephalitis patient in Malaysia in 1952 (also referred to as the Muar strain), and it remained the only known instance of this genotype for over 50 years (Hasegawa et al., 1994; Solomon et al., 2003) . Recently, the GV JEV genome has been identified in Culex mosquitoes in China in 2009 and in South Korea in 2010 and 2012 (Kim et al., 2015; Takhampunya et al., 2011) . A group in China succeeded in isolating a new GV strain (referred to as the XZ0934 strain) from C. tritaeniorhynchus . In South Korea, genomes of GV JEV were detected in Culex bitaeniorhynchus, Culex orientalis and Culex pipiens, but none was identified in the major JEV vector, C. tritaeniorhynchus (Kim et al., 2015; Takhampunya et al., 2011) . These findings raise the possibility that other species of Culex mosquitoes may be involved in the natural transmission cycle of the GV strain of JEV. Thus, GV JEV may also be emerging in other endemic areas, and more attention needs to be focused on investigating the dynamics of circulating JEV strains in these areas.
As only two GV strains, Muar and XZ0934, have been isolated thus far, and biological studies on the features of GV JEV have been very limited, the growth and pathogenic properties of GV JEV remain poorly understood. The spread of JEV strains, other than GIII, into endemic areas makes it imperative that systematic evaluation is conducted on the protective efficacy of current GIII-derived JEV vaccines against other JEV genotypes. Previous reports have called attention to the reduced neutralizing potency of inactivated and live-attenuated GIII JE vaccines against circulating GI JEV (Fan et al., 2012 (Fan et al., , 2013 . In contrast, other researchers have shown that inactivated and live-attenuated JEV vaccines are effective against both GIII and GI JEV strains that are prevalent in China , and inactivated vaccines used for European travellers induce protective levels of neutralizing antibodies against GI-GIV JEV (Erra et al., 2013a, b) . Thus, the efficacy of the current JEV vaccines against heterologous genotypes remains unresolved. Furthermore, these studies did not assess the Beijing-1 strainderived vaccine that is currently available in Japan, the Nakayama strain-derived vaccine or a GV JEV strain as a target virus.
To uncover the characteristics of GV JEV, we investigated in vitro growth and pathogenicity in mice for the GV JEV Muar strain. We also evaluated the protective efficacy of the inactivated JEV vaccines against the Muar strain, as well as several GI and GIII JEV strains.
RESULTS

In vitro growth properties of the Muar strain
To characterize the growth of the GV Muar strain in vitro, we first compared the plaques induced by the Muar strain to those of GI Mie/41/2002 strain and GIII Beijing-1 strains in Vero cells (Fig. 1a) . The plaque size induced by Muar (mean diameter + SEM: 0.98 + 0.03 mm) was less than that of Mie/41/2002 (1.89+0.05 mm; Pv0.001) but was similar to that of Beijing-1 (1.02+0.03 mm; P50.37). Similar results were obtained using a replication kinetics assay for these viruses in Vero cells and BHK-21 cells (Fig. 1b, c) . These results suggested that the growth of Muar was similar to that of Beijing-1 in IFN response-deficient cells. Our previous report showed that, in contrast to the results in Vero cells, the steady-state number of infectious particles for Beijing-1 was apparently higher than that of Mie/41/2002 in mouse neuroblastoma-derived N18 cells (Tajima et al., 2010) . We next examined the growth properties of Muar in N18 cells (Fig. 1d) . However, the growth rate of Muar in N18 cells was slower than the other strains, and the infectious particles of Muar at steady state were 100-fold and 10-fold less than those of Beijing-1 and Mie/41/2002, respectively. These data indicated that Muar might exhibit a reduced amplification in N18 cells, and the characteristics of the Muar strain were clearly different from those of the Beijing-1 and Mie/41/2002 strains in vitro. Using real-time reverse transcription-PCR, we also confirmed in all three cultured cells that the quantity of viral genomes in the supernatant and in the cells infected with the viruses corresponded to those of the virus titres (data not shown), indicating that the reduced growth of Muar in cultured cells did not reflect defective particle assembly and secretion.
Virulence of the Muar strain in mice
Next, we examined the pathogenicity of the Muar strain in mice. Mice were infected intraperitoneally (i.p.) with strain Muar, Beijing-1 or Mie/41/2002 and observed for 3 weeks (Table 1) . Our previous report using the Beijing-1 and Mie/41/2002 strains demonstrated that the growth characteristics of some JEV strains in N18 cells were positively correlated with neuroinvasiveness in mice (Tajima et al., 2010) ; therefore, we speculated that the Muar strain might exhibit a lower virulence in mice compared with the Beijing-1 and Mie/41/2002 strains. In the groups infected with 10 3 , 10 4 and 10 5 p.f.u., more than 90 % of the mice infected with Muar or Beijing-1 died; however, less than 30 % of the mice infected with Mie/41/2002 died. The survival curves for the Muar-infected groups were similar to those of the Beijing-1-infected groups. These results indicated that, in contrast to the growth kinetics in N18 cells, neuroinvasiveness of Muar was equivalent to that of Beijing-1 and was significantly higher than that of Mie/41/ 2002 in mice.
Neutralizing ability of inactivated JEV vaccines against Muar and recombinant intertypic JEVs
We next evaluated the ability of inactivated Nakayama and Beijing-1 vaccines, which were produced in Japan, to induce neutralizing antibodies against the Muar strain. We also used three GIII and 11 GI viruses with differing amino acid sequences in the E protein as target viruses (Supplementary Table S1 , available in the online Supplementary Material). The E protein is the major structural protein that constitutes the surface structure of the virus particles, and a majority of neutralizing antibodies bind to the E protein and can inhibit viral infection (Wu et al., 2003) . Serum samples collected from mice at 14 days after initial immunization with twofold-diluted and eightfold-diluted JE vaccines were used for a plaque reduction neutralization test (PRNT), and the value of 50 % reduction relative to the non-serum control (PRNT 50 ) for each virus was determined (Table 2 ). In the sera of mice that were immunized with twofold dilutions, the PRNT 50 titre against GI and GIII viruses was between 1 : 80 and 1 : 320. In those with eightfold dilutions, it was between 1 : 40 and 1 : 160. We statistically compared the PRNT 50 titres of sera against GI viruses to those against GIII viruses using a parametric Welch's t-test and a non-parametric Mann-Whitney U test. No significant differences (Pw0.05) were observed between the GI group and GIII group in all cases, indicating that the neutralizing efficacy of inactivated Nakayama and Beijing-1 vaccines against the GI strains was similar to that for the GIII strains. In contrast to the GI and GIII strains, the PRNT 50 titres in the sera of mice immunized against GV Muar were fourfold less than those against the GI and GIII strains. These results suggested that the neutralizing capacity of the JEV vaccines against GV JEV was considerably lower than that against GI and GIII JEV. We also examined the neutralizing potency (PRNT) of sera obtained from mice at 2 and 4 months after the initial immunization for the twofolddiluted and eightfold-diluted Nakayama and Beijing-1 vaccines (Table 3) . Two vaccine strains, two GI strains, three GIII strains and one GV strain were used as target viruses. The PRNT 50 titres for GV Muar were less than those for GI and GIII JEV, indicating that the neutralization capacity of the inactivated JEV vaccines was relatively weak against the GV Muar strain.
A comparison of the E protein amino acid sequences among the viral genotypes showed a higher homology between GI and GIII than that between GI and GV or that between GIII and GV (data not shown). There were 40 residues (8.0 %) that differed between Beijing-1 and Muar, and 44 residues (8.8 %) were different between Nakayama and Muar. In contrast, fewer than 12 residues (2.4 %) were different between the vaccine strains and the GI strains, and fewer than eight residues (1.6 %) were different between the vaccine strains and the GIII strains (Supplementary Table S2 and S3). Other GV strains, XZ0934 and 10-1827, also showed similar homology to the vaccine strains, and only two residues (0.4 %) were different between the XZ0934 and 10-1827 strains. These findings raised the possibility that the neutralization potency of the inactivated vaccines against the other GV strains was also relatively weak. To examine the efficacy of the vaccines against GV strains other than Muar, we generated recombinant intertypic JEVs rJEV-E Muar -M41 and rJEV-E XZ0934 -M41, which contained the majority of the E region of Muar and XZ0934, respectively, in the backbone of the Mie/41/2002 genome. We also generated rJEV-E Nakayama -M41 and rJEV-E Beijing-1 -M41 as control viruses for use in the neutralization assay (Tajima et al., 2010) . The PRNT 50 titres in the sera from mice immunized with the vaccines against rJEV-E Muar -M41 and rJEV-E XZ0934 -M41 were clearly less than those against the parental virus Mie/41/2002, rJEV-E Nakayama -M41 and rJEV-E Beijing-1 -M41 (Table 4 ). These results indicated that the neutralization ability of the vaccines may be weak against both Muar and other GV JEV strains. Table 2 . PRNT 50 titres of pooled mouse sera, which were recovered from mice at 14 days after the initial immunization with the inactivated Nakayama and Beijing-1 vaccines, against GI, GIII, GV and vaccine strains 
Protection efficacy of JEV vaccines against Muar infection in mice
To examine whether immunization of mice with the inactivated JE vaccines inhibited the onset of Muar-induced disease, mice that were vaccinated with the inactivated Beijing-1 vaccine were inoculated i.p. with 10 4 p.f.u. Muar or Beijing-1 strain (Table 5 ). Mice vaccinated with twofold-diluted vaccine had a 100 % survival rate after inoculation with Beijing-1 or Muar. Fourteen of 16 mice (87.5 %) and 12 of 16 mice (75 %) that were vaccinated with 32-fold-diluted vaccine survived after infection with Beijing-1 or Muar, respectively. There was no significant difference in the survival rates between the Beijing-1-infected and Muar-infected groups. These results suggested that the protection efficacy of the Beijing-1 vaccine against infection with Muar was similar to that against infection with Beijing-1 in vivo.
Neutralizing ability of sera from Muar-infected mice against various JEVs
Finally, we assessed the ability of GV Muar-infected mouse sera to block the infection of GI and GIII JEVs in vitro using a neutralization assay (Table 6 ). The PRNT 50 titre against Muar was two-or fourfold higher than that against two GI, three GIII and the Beijing-1 strains, although the titre against Nakayama was equivalent to that against Muar. Thus, we confirmed that sera from Muar-infected mice were able to neutralize infection by GI and GIII strains; however, the neutralization potency of these sera against GI and GIII viruses was weaker than that against Muar.
DISCUSSION
To date, only two GV JEV strains have been isolated and amplified in vitro. Therefore, the characteristics of GV JEV remain poorly understood. In this study, we examined the in vitro growth properties and in vivo pathogenicity of the GV strain Muar. Furthermore, we investigated the potential of inactivated JEV vaccines that are currently available in Japan to induce a protective immune response against GV JEV using mouse models. Our results indicate that GV JEV has different growth, pathogenic and antigenic characteristics compared with GI and GIII JEV.
Our previous report suggested that there is a correlation between the growth characteristics of JEV in mouse neuroblastoma N18 cells and virulence in mice (Tajima et al., 2010) . The growth rate of Muar was less than that of the Table 3 . PRNT 50 titres of pooled mouse sera, which were recovered from mice at 2 and 4 months after initial immunization with the inactivated Nakayama and Beijing-1 vaccines, against GI, GIII, GV and vaccine strains (Tajima et al., 2010) . Other reports have also highlighted the importance of the E protein as a determinant of pathogenicity (Monath et al., 2002; Sumiyoshi et al., 1995; Zhao et al., 2005) . In contrast, our group determined that an amino acid substitution in the JEV NS4A protein alters virulence in mice (Yamaguchi et al., 2011) . To clarify the regions responsible for increased pathogenicity in the Muar genome, various GI-GV intertypic and point mutant viruses may be required. Recently, Ishikawa et al. (2015) identified the infectious molecular clone and reporter replicon of the Muar strain, which is also beneficial for generally understanding the characteristics of GV JEV. In addition, de Wispelaere et al. (2015) constructed a molecular clone of the GV XZ0934 JEV strain and demonstrated that this recombinant GV virus exhibited a greater pathogenicity in BALB/c mice than that of GIII JEV.
The neutralization tests using the vaccinated mouse sera indicated that both the Nakayama and Beijing-1 vaccines induced sufficient neutralizing antibodies against GI JEV. However, these vaccines induced fewer neutralizing antibodies against GV Muar or the recombinant intertypic JEVs, which contain the E protein from the GV Muar or XZ0934 strains. Furthermore, the sera from Muar-infected mice had a lower neutralization titre against GI and GIII viruses compared with the Muar strain. These data indicated that GV JEV may be distinct from GI and GIII JEV in antigenicity. The E protein sequences between GI and GIII JEV differ by approximately 3 % (Solomon et al., 2003) . However, this number increases to 8.8-9.2 % between GV strains and the Nakayama strain, and 8.2-8.6 % between GV strains and the Beijing-1 strain (Supplementary Tables S2 and S3 ). The decrease in homology between the vaccine strains and the GV strains might be responsible for the observed weak efficacy of the vaccines against the Muar strain and recombinant JEVs that contained GV E proteins. The amino acid differences between the vaccine strains and the GI strains did not exceed 2.4 %, indicating that the difference may not influence the efficacy of the vaccines. Previous studies have identified individual residues within the E protein that are related to the recognition of JEV by neutralizing antibodies (Crill & Chang, 2004; Goncalvez et al., 2008; Kobayashi et al., 1985; Morita et al., 2001; Vogt et al., 2009; Wu et al., 2003) . Although the sequence variation between the vaccine strains and GV strains do not correspond to epitope residues, only a limited number of residues could be responsible for the decreased neutralization ability of the vaccines against GV strains. All inactivated and liveattenuated JE vaccines that are currently available are derived from GIII strains. Our results indicate that live-attenuated GIII-derived vaccines may have a reduced potency in inducing neutralizing antibodies against GV JEV. In this report, we used vaccinated mouse sera for all neutralization analyses. It is generally accepted that neutralizing antibodies with a PRNT 50 of 1 : 10 or greater are sufficient to protect from the onset of JE (Kitano & Oya, 1996; Kurane & Takasaki, 2000) . Further studies using human sera from JEV vaccineimmunized healthy and JE case individuals will be needed in order to validate our findings in humans.
In contrast to the results of the neutralization tests, the challenge analysis in mice immunized with the inactivated Beijing-1 vaccine showed no clear difference in mortality between the Beijing-1-infected and Muar-infected groups for either vaccine concentration. This indicates that the ability of the Beijng-1 vaccine to block the onset of encephalitis by Muar might be comparable to that by Beijing-1 in vivo.
Our results indicated that the PRNT 50 titres of twofoldand eightfold-diluted Beijing-1 vaccine against Muar were 1 : 20 and 1 : 10, respectively, which were 16-fold less than those against Beijing-1 (1 : 320 and 1 : 160, respectively) ( Table 2 ). These findings suggest that, although the neutralization potency of the Beijing-1 vaccine against GV JEV is weaker than those against GI and GIII JEV, the potency of the vaccine is not critical to inhibit disease caused by GV JEV, as long as the titre exceeds a threshold of 1 : 10. We inoculated 10 4 p.f.u. Muar and Beijing-1 per 5-weekold mouse in the protection assay, as this virus titre was sufficient to kill all 3-week-old mice, as shown in Table 1 . However, only 50 % of the mice died in the non-vaccinated Beijing-1-inoculated group, while over 90 % of mice died in the non-vaccinated Muar-inoculated group. It is possible that Muar may exhibit a modestly increased virulence compared with Beijing-1 when 5-week-old mice are used for the evaluation of neuroinvasiveness.
For more than 50 years, the Muar strain was the only example of GV. Recently, several GV genomes were detected in Culex mosquitoes in China and South Korea (Kim et al., 2015; Takhampunya et al., 2011) , but there has been no GV JEV detected in Japan to date. However, in both Japan and South Korea, a GIII-to-GI shift occurred in the early 1990s, raising the possibility that GV JEV has already invaded Japan. Recently, Kim et al. (2015) suggested that two new vector mosquito species might play a role in the transmission of GV JEV. Continuous and careful monitoring of the spread of GV viruses must be undertaken. In South Korea, 26 JE patients were reported in 2010, representing a 12-fold increase compared with the mean number that was reported over the previous 26 years (Seo et al., 2013) . The relationship between the increase in the number of JE patients in South Korea in 2010 and the emergence of GV JEV remains unknown. Continuous isolation of JEV from JE patients, mosquitoes and other amplifying hosts is important to understand the effects of GV emergence.
METHODS
Cells, virus strains and genetic analysis. Vero cells (strain 9013) and BHK-21 cells were maintained at 37 uC with 5 % CO 2 in Eagle's minimal essential medium supplemented with 10 % heat-inactivated FBS and 100 U penicillin/streptomycin ml 21 . The JEV strains used in this study are listed in Supplementary Table S1 . Briefly, we used two JEV vaccine strains (Nakayama and Beijing-1), 11 GI strains, three GIII strains and one GV strain. All of the GI and GIII strains were isolated in Japan, while the GV Muar strain was isolated from a patient with encephalitis in Malaysia in 1952. Working virus stocks were prepared in Vero cells. The nucleotide sequence of the E region containing 1500 nt was determined for all strains used in this study, including the two vaccine strains (Nakayama and Beijing-1). These nucleotide sequences and their corresponding amino acid sequences were subjected to sequence alignments using GENETYX v.11 genetic software (Genetyx).
Analysis of growth kinetics and plaque morphology. The growth properties of the JEV strains were analysed as described previously (Tajima et al., 2010) . Briefly, cells were plated into six-well culture plates and infected with the JEV strains at an m.o.i. of 0.01. Aliquots of the medium were removed periodically and their viral titres were determined using a plaque assay on Vero cells. To evaluate plaque size, Vero cells were plated in 12-well plates and inoculated with the viruses. Four days after inoculation, the cells were fixed using a 10 % formalin solution in PBS and subsequently stained with methylene blue. The diameter of 20 plaques was measured and the mean plaque size in mm+SEM was calculated.
Production of recombinant JEV. Four recombinant molecular clones, rJEV-E Beijing-1 -M41/pMW119, rJEV-E Nakayama -M41/pMW119, rJEV-E Muar -M41/pMW119 and rJEV-E XZ0934 -M41/pMW119, were constructed in the GI JEV strain Mie/41/2002 backbone as described previously (Tajima et al., 2010) . Briefly, the E region, from position 927 to 2410, of rJEV(Mie/41/2002)/pMW119 was replaced with the corresponding region of the Beijing-1, Nakayama, Muar or XZ0934 strain. The recombinant viruses were recovered by transfection of in vitro-transcribed recombinant viral RNA into Vero cells, as described previously (Tajima et al., 2010) .
Mouse vaccination. Mouse experiments were performed in accordance with the Guidelines for Animal Experiments Performed at National Institute of Infectious Diseases published by the Animal Welfare and Animal Care Committee of the National Institute of Infectious Diseases, Japan. Mouse brain-derived inactivated JE Nakayama vaccine (Biken) and Vero cell-derived inactivated JE Beijing-1 vaccine (Biken) were used for immunization of the mice. Both vaccines were diluted 1 : 2 and 1 : 8 with PBS. Groups of inbred ddY mice (4 weeks old, n530; Japan SLC) were vaccinated i.p. with 0.5 ml diluted vaccine and immunized again 1 week after the initial immunization. The immunized mice were sacrificed at 14 days, 2 months or 4 months after the initial immunization, and their sera were pooled independently (10 mice per pool) for each period. These sera were used to measure neutralization antibody titres as described below.
Mouse challenge test. For evaluation of neuroinvasiveness, groups of ddY mice (3 weeks old, n510) were inoculated i.p. with 100 ml serially diluted recombinant virus in 0.9 % NaCl solution. The mice were observed for 3 weeks after inoculation to determine survival rates. Survival curve comparisons were performed using Prism software (GraphPad software) statistical analysis with a log-rank (Mantel-Cox) test. To evaluate the protection efficacy of the vaccines, groups of ddY mice (3 weeks old, n514 or 15) were vaccinated i.p. with 0.5 ml inactivated Beijing-1 vaccine diluted 1 : 2 or 1 : 32 and were immunized again 1 week after the initial immunization. The immunized mice were inoculated i.p. with 100 ml of 10 4 p.f.u. Beijing-1 and Muar strains. The mice were observed for 3 weeks after inoculation to determine survival rates, and survival curve comparisons were performed as described above. To obtain anti-Muar antisera, ddY mice (3 weeks old, n54) were inoculated i.p. with 100 ml containing 10 p.f.u. Muar and were inoculated subsequently with 100 ml containing 10 2 p.f.u. Muar at 11 days after the initial inoculation. The Muar-infected mice were sacrificed 22 days after the first inoculation to collect pooled antisera, and the sera were used for neutralization tests.
PRNT. Neutralizing antibodies to JEV were measured using the PRNT method. Each JEV strain was combined at a 1 : 1 ratio with twofold serial dilutions (1 : 10 to 1 : 640) of the sera from mice immunized with the Nakayama vaccine or the Beijing-1 vaccine and then incubated at 35 uC for 90 min. Vero cell monolayers were inoculated with these mixtures in 12-well plates and incubated at 35 uC for 90 min. Subsequently, overlay medium containing 1 % methylcellulose was added and the cells were incubated at 35 uC for 4-6 days. The cells were fixed using a 10 % formalin/PBS solution and stained using methylene blue. The PRNT 50 titre was defined as the reciprocal of the highest dilution that resulted in 50 % reduction relative to the non-serum control.
